Select Page

Enabling Precision Medicine

Transforming Cancer Care with Genomic Insights

Unlock the potential of personalized medicine with our cutting-edge comprehensive genomic tests

Revolutionizing Cancer Diagnostics with AI

At Oncophenomics, we’re leading the way in personalized medicine with our cutting-edge companion diagnostics and liquid biopsy tests. Our innovative approach allows for tailored treatments that greatly improve patient outcomes.

Impact on Cancer Treatment

Our comprehensive liquid biopsy test, Fathom Dx, integrates both genomic and epigenomic biomarkers to provide a holistic view of the cancer landscape. This test includes tumor agnostic biomarkers such as TMB, MSI, NTRK gene fusions, and Homologous Recombination Deficiency status, all at no extra cost. By matching patients with the most effective therapies, we aim to significantly improve treatment outcomes.

Comprehensive Biomarker Inclusion

Advanced Liquid Biopsy Test

Our comprehensive liquid biopsy test stands out by incorporating tumour agnostic biomarkers, ensuring a thorough and precise analysis. This test includes a wide range of genomic and epigenomic markers, such as TMB, MSI, NTRK gene fusions, and Homologous Recombination Deficiency status, all at no extra cost. Utilizing clean white space and a Sans Serif font, we present this cutting-edge technology designed to enhance cancer diagnostics and treatment.

Discover More

Join us in our mission to promote precision medicine in oncology. Learn more about our comprehensive liquid biopsy test and how it can make a difference in cancer diagnostics and treatment. Contact us today for more information and take the first step towards better patient outcomes.